PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer - Loibl, S; von Minckwitz, G; Schneeweiss, A (J Clin Oncol, 2014)
et al.